Gómez-Barrena Enrique, Padilla-Eguiluz Norma G, Rosset Philippe
Servicio de Cirugía Ortopédica y Traumatología, Hospital La Paz-IdiPAZ, Universidad Autónoma de Madrid, Madrid, Spain.
Service de Chirurgie Orthopédique et Traumatologie, CHU Tours, Université de Tours, Tours, France.
EFORT Open Rev. 2020 Oct 26;5(10):574-583. doi: 10.1302/2058-5241.5.190062. eCollection 2020 Oct.
Multifactorial aetiology defines non-unions, with a biological and a mechanical distortion of the timeline of bone healing.Research on new advances to increase osteogenesis and promote non-union healing is strongly directed towards new forms of cell products.Basic science and research on non-union treatments is needed to compile preclinical data on new treatments.Bone marrow concentration and expanded mesenchymal stromal cells still require extensive clinical research to confirm efficacy in non-union treatment.Solid preclinical studies, precise cell product definition and preparation, and appropriate ethical and regulatory approvals are needed to assess new advanced therapy medicinal products. Cite this article: 2020;5:574-583. DOI: 10.1302/2058-5241.5.190062.
多因素病因决定了骨不连,其存在骨愈合时间线的生物学和力学扭曲。旨在增加骨生成和促进骨不连愈合的新进展研究主要针对新型细胞产品形式。需要开展骨不连治疗的基础科学和研究,以汇编有关新治疗方法的临床前数据。骨髓浓缩物和扩增的间充质基质细胞在骨不连治疗中的疗效仍需广泛的临床研究来证实。评估新的先进治疗医药产品需要扎实的临床前研究、精确的细胞产品定义和制备,以及适当的伦理和监管批准。引用本文:2020;5:574 - 583。DOI:10.1302/2058 - 5241.5.190062。